Perspectives in Clinical Research

ETHICS EDUCATION
Year
: 2020  |  Volume : 11  |  Issue : 4  |  Page : 174--177

Consent concerns in clinical trials of investigational therapies for COVID-19: Vulnerability versus voluntariness


Arun Bhatt 
 Consultant – Clinical Research and Drug Development, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Arun Bhatt
303-4, Dheeraj Valley 3/C, Mohan Gokhale Road, Goregaon East, Mumbai - 400 063, Maharashtra
India

Obtaining informed consent from vulnerable patients participating in clinical trials of investigational therapies for COVID-19 is a major ethical challenge. Ethical and operational considerations – voluntariness, waiver, timing, time, documentation, and responsibilities of the sponsor, the investigator, and the ethics committee – are discussed briefly.


How to cite this article:
Bhatt A. Consent concerns in clinical trials of investigational therapies for COVID-19: Vulnerability versus voluntariness.Perspect Clin Res 2020;11:174-177


How to cite this URL:
Bhatt A. Consent concerns in clinical trials of investigational therapies for COVID-19: Vulnerability versus voluntariness. Perspect Clin Res [serial online] 2020 [cited 2022 Aug 19 ];11:174-177
Available from: http://www.picronline.org/article.asp?issn=2229-3485;year=2020;volume=11;issue=4;spage=174;epage=177;aulast=Bhatt;type=0